LCP1 promotes ovarian cancer cell resistance to olaparib by activating the JAK2/STAT3 signalling pathway
These findings indicate that LCP1 expression may play an important role in the resistance of OC to olaparib by activating the JAK2/STAT3 signaling pathway and EMT. LCP1 could be a potential therapeutic target for patients with OC who are resistant to olaparib. Our study provides a new mechanism of olaparib resistance.
Authors
- Hongqi Li (ORCID: https://orcid.org/0000-0001-7150-5928)
- Wei Li (ORCID: https://orcid.org/0000-0001-8411-0394)
- Lanlan Zhao (ORCID: https://orcid.org/0000-0001-8280-443X)
- Minxue Gai
- Guoyu Jin
- Ming Liu (ORCID: https://orcid.org/0000-0002-0666-3564)
- Fei Wang (ORCID: https://orcid.org/0000-0001-6344-1872)
Institutions
- Shandong University of Traditional Chinese Medicine (CN)
- Shandong University (CN)
- Shandong Provincial Hospital (CN)
- Qilu Hospital of Shandong University (CN)
Publication Details
- Journal
- Cancer Biology & Therapy
- Published
- 2024-11-26
- DOI
- https://doi.org/10.1080/15384047.2024.2432117
- Citations
- 5
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.41